Apalutamide Plus Abiraterone Acetate and Prednisone in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Apalutamide Plus Abiraterone Acetate and Prednisone Versus Placebo Plus Abiraterone and Prednisone in Metastatic Castration-Resistant Prostate Cancer (ACIS): A Randomised, Placebo-Controlled, Double-Blind, Multinational, Phase 3 Study
Lancet Oncol 2021 Sep 30;[EPub Ahead of Print], F Saad, E Efstathiou, G Attard, TW Flaig, F Franke, OB Goodman, S Oudard, T Steuber, H Suzuki, D Wu, K Yeruva, P De Porre, S Brookman-May, S Li, J Li, S Thomas, KB Bevans, SD Mundle, SA McCarthy, DE RathkopfFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.